Statement: For all adverse event types in the primary trial, at least one case was recorded.
Primary_evidence: Adverse Events 1:   Total: 6/8 (75.00%)   Thrombocytopenia 1/8 (12.50%)   Hypertension 1/8 (12.50%)   Hepatotoxicity 3/8 (37.50%)   Pancreatectomy * 1/8 (12.50%)